JAMA:减少血管紧张素暴露对老年重症患者血管扩张性低血压90天死亡率的影响

2020-02-28 patrick 大医编

通常向重症监护病房(ICU)患者施用升压药以升高血压。平衡血管加压药的风险和益处是一项挑战,特别是在老年患者中。

通常向重症监护病房(ICU)患者施用升压药以升高血压。平衡血管加压药的风险和益处是一项挑战,特别是在老年患者中。

为确定是否通过允许的低血压(平均动脉压[MAP]目标为60-65 mm Hg)减少对血管加压药的接触以降低死亡率,近日有学者探究了减少血管紧张素暴露对老年重症患者血管扩张性低血压90天死亡率的影响。

这是一项在英国的65个ICU中进行了一项多中心,务实的随机临床试验,纳入2600名年龄在65岁或以上且患有血管舒张性低血压的随机患者。该研究于2017年7月至2019年3月进行,后续研究于2019年8月完成。干预措施根据MAP指标(60-65 mm Hg,允许性低血压)(n = 1291)或根据常规护理(n = 1307),将患者按1:1的比例随机分配至血管加压药。主要临床结果是90天全因死亡率。

在2600名随机分组的患者中,除去拒绝或撤消同意的患者后,主要结果分析中包括2463名(95%)(平均[SD]年龄75岁[7岁];男性1387 [57%])。该研究发现与常规护理组相比,随机分配至允许性低血压组的患者接受升压药的风险较低(中位持续时间33小时vs 38小时;中位数差异为–5.0;95%CI为–7.8至–2.2小时;去甲肾上腺素当量中位数,分别为17.7 mg和26.4 mg;中位数差异为–8.7 mg;95%CI为–12.8至-4.6 mg)。在90天时,允许的低血压中有500例死亡(1221)(41.0%),而常规护理组中有544例(1242)(43.8%)死亡(绝对风险差异为-2.85%; 95%CI为-6.75至1.05;P = .15)(未经调整的相对风险,0.93; 95%CI,0.85-1.03)。

如果对预先设定的基准变量进行调整,则90天死亡率的优势比为0.82(95%CI,0.68至0.98)。许可治疗组报告了79例患者的严重不良事件(6.2%),常规治疗组报告了75例患者(5.8%)的严重不良事件。最常见的严重不良事件是急性肾功能衰竭(41 [3.2%] vs 33 [2.5%])和室上性心律失常(12 [0.9%] vs 13 [1.0%])。

该研究认为在接受血管舒张降压治疗的65岁或65岁以上患者中,与常规治疗相比,放宽性低血压并未导致90天死亡率有统计学上的显着降低。但是,在解释研究的临床重要性时,应考虑主要结果的点估计周围的置信区间。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
    2020-09-28 lsj637
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1684827, encodeId=3060168482e4e, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Mon Sep 28 09:00:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705684, encodeId=fa1f1e0568453, content=<a href='/topic/show?id=ac7e89660ed' target=_blank style='color:#2F92EE;'>#血管扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89660, encryptionId=ac7e89660ed, topicName=血管扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cbe31021348, createdName=pyaili, createdTime=Fri May 08 23:00:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284084, encodeId=ffd7128408487, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367400, encodeId=c7c4136e40068, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589329, encodeId=020e158932979, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Feb 29 16:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035934, encodeId=f7611035934d7, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Feb 28 04:00:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
    2020-02-28 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Crit Care Med:应用血管紧张素安全么?

血管紧张素II是具有血管加压素和内分泌活性的内源性激素。该文章是一篇对IV血管紧张素II的安全性评估的系统综述。

JAHA:血管紧张素受体蛋白酶抑制剂在改善心脏重塑方面优于ACEI

PARADIGM‐HF临床研究结果显示血管紧张素受体蛋白酶抑制剂(ARNI)在降低心血管死亡率方面优于血管紧张素转换酶抑制剂,但是ARNI对心脏逆向重塑(CRR)的影响尚不清楚。本次荟萃分析比较了ARNI和血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对CRR的影响。最终共纳入分析了来自20个临床研究的10175名患者,分析结果显示ARNI可以改善心衰伴射血分数降低患者的心功能,包括纽约心功能分级(

Hypertension:怀孕时高果糖摄入可诱导多代子孙发生心脏代谢综合征

虽然母体高果糖摄入可诱发成年子女发生心脏代谢综合征,但它是否会诱发连续几代人发生高血压尚未有相关研究。Ho Yeong Seong等人推测母亲高果糖摄入可诱发多代子孙的肾素-血管紧张素-醛固酮系统激活。给妊娠小鼠的饮用水中加入20%的果糖,其第一代到第四代后代在没有果糖的情况下喂养长大。监测各代小鼠的血压,检测其mRNA表达水平,同时评价纤维化程度。与对照组相比,母体高果糖摄入显著增加了第一代和第

赖诺普利氢氯噻嗪片,一个理想的单片复方降压药!

从1981年第一个血管紧张素转换酶抑制剂(ACEI)卡托普利上市至今,全球共计约有20种ACEI陆续上市,目前ACEI仍作为一线降压药物担当抗高血压治疗的主力军。

NEJM:血管紧张素-脑啡肽酶抑制剂对急性失代偿性心力衰竭患者疗效分析

由此可见,在因急性失代偿性心力衰竭而住院且射血分数降低的心力衰竭患者中,开始使用sacubitril-valsartan治疗相比于依那普利治疗可导致NT-proBNP浓度更大程度地降低。肾功能恶化、高钾血症、症状性低血压和血管性水肿的发生率在两组之间没有显著差异。

Hypertension:早产年轻人肾脏大小、肾功能、血管紧张素和血压分析

由此可见,与足月产成人相比,早产的青年人肾脏较小,尿白蛋白与肌酐比值较高,血压和循环Ang I水平也较高。肾脏较小的早产成人具有较高的血压。